UNASSIGNED: e18570^ Background: Relapse continues to be a challenge affecting @entity1 's survival in @entity1582 . Chemoresistance of @entity1582 stem cell MMSC (CD138(-) @entity2225 (+)) remains an obstacle to complete disease eradication. METHODS: We utilized the presence of @entity2225 antigen on MMSC to target them with ex vivo expanded anti-CD3 activated autologous T cells armed with anti-CD3 x anti- @entity2225 bispecific antibody (aATC), to determine whether anti-MMSC immunity could be induced. @entity1 were given two infusions of 10(10) aATC 1 week apart after completing @entity1582 induction therapy and prior to autologous stem cell transplant ASCT. RESULTS: Twelve @entity1 (pts) were enrolled. Nine pts have received their aATC, ASCT, are evaluable for safety, and immune correlative studies. These nine pts are alive at a median 159 days after ASCT (115-360). Two pts have relapsed. There were no dose-limiting @entity137 (DLT) associated with ATC infusions. One pt developed catheter related @entity4461 . Infusional grade II/III @entity137 included: 8 @entity551 , 16 chills, and 1 fever. All pts engrafted between days (11-23). Flirgrastim was used only if engraftment was delayed beyond day 15. Immune testing suggests that aATC infusions induced anti @entity1582 immune responses in 7/9 pts prior to ASCT. CONCLUSIONS: Infusions of aATC to target @entity2225 pre ASCT seems to be feasible and safe. Further studies to determine the efficacy of this approach are needed. [Table: see text].

Phase I trial: Pretransplant targeting of XXXX stem cell (MMSC) with armed activated T cells (aATC).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma'] @entity4461 :: ('MESH:D020141', 'Disease') :: ['blood clot'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
